Patients with cardiac failure with reduced ejection fraction (HFrEF) are sub treated when you look at guideline-directed medical therapy (GDMT). The aim of this study was to assess if, using an electronic registry, we can alert treating physicians and optimize medical treatment. 100 healthcare professionals (doctors, nurses, etc) were randomized to receiving and alert…
ESC 2021 | Empagliflozin in Heart Failure with Reduced and Preserved Ejection Fraction
The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death or hospitalization for heart failure (HF) in both patients with reduced and with preserved function. The primary endpoint (a composite of death and hospitalization for HF) was reduced by 21% on a relative basis with sodium/glucose cotransporter 2…
ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups
Dapagliflozin (a sodium glucose co-transporter 2 [SGLT2] inhibitor), when indicated concomitantly with standard therapy, reduces significantly the risk of worsening heart failure events and cardiovascular events, and improves symptoms in patients with heart failure and reduced ejection fraction according to this new work presented during last Sunday’s scientific sessions at the European Society of Cardiology…
How can we classify aortic stenosis in patients who underwent TAVR?
Courtesy of Dr. Carlos Fava. Aortic stenosis can present different hemodynamic patterns, such as low flow and low gradient with reduced or preserved ventricular function. However, evidence on the evolution of different hemodynamic patterns after transcatheter aortic valve replacement (TAVR) is limited. This study consisted in a retrospective analysis of 368 patients who underwent TAVR. The population was divided in…